PAVmed Inc. (NASDAQ:PAVM) CFO Dennis M. Mcgrath acquired 6,000 shares of PAVmed stock in a transaction that occurred on Tuesday, August 22nd. The shares were purchased at an average cost of $4.21 per share, with a total value of $25,260.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
PAVmed Inc. (NASDAQ PAVM) traded down 0.878% during trading on Friday, hitting $4.064. The stock had a trading volume of 1,200 shares. The firm’s 50-day moving average price is $3.74 and its 200-day moving average price is $4.78. The stock’s market cap is $54.18 million. PAVmed Inc. has a 1-year low of $2.54 and a 1-year high of $14.49.
PAVmed (NASDAQ:PAVM) last issued its earnings results on Monday, August 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.01. On average, equities research analysts predict that PAVmed Inc. will post ($0.72) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Dennis M. Mcgrath Acquires 6,000 Shares of PAVmed Inc. (PAVM) Stock” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://stocknewstimes.com/2017/08/25/dennis-m-mcgrath-acquires-6000-shares-of-pavmed-inc-pavm-stock.html.
Separately, ValuEngine cut PAVmed from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th.
A hedge fund recently bought a new stake in PAVmed stock. Fusion Family Wealth LLC bought a new position in shares of PAVmed Inc. (NASDAQ:PAVM) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 55,745 shares of the company’s stock, valued at approximately $251,000. Fusion Family Wealth LLC owned 0.42% of PAVmed as of its most recent SEC filing. Institutional investors own 0.70% of the company’s stock.
About PAVmed
PAVmed Inc operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device.
Receive News & Ratings for PAVmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
